From the Research
The primary purpose of an ADMA test is to assess the risk of cardiovascular disease and mortality by measuring the levels of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in the blood. The ADMA test is used to evaluate the levels of asymmetric dimethylarginine, a naturally occurring compound that inhibits nitric oxide production, which can be elevated in conditions like cardiovascular disease, kidney disease, and diabetes.
- Normal ADMA levels typically range from 0.4-0.7 μmol/L, though reference ranges may vary between laboratories.
- Elevated ADMA levels are associated with endothelial dysfunction, as ADMA blocks the enzyme nitric oxide synthase, reducing nitric oxide availability, which can lead to impaired blood vessel dilation and increased risk of atherosclerosis.
- According to a study published in 2018 1, high plasma ADMA levels were associated with the occurrence of cardiovascular death and the development of type 2 diabetes mellitus in patients with hypertension.
- Another study published in 2009 2 found that ADMA was significantly associated with all-cause mortality, particularly in non-diabetic individuals.
- The test is not routinely performed in clinical practice but is more commonly used in research settings to study cardiovascular risk factors, as stated in a review published in 2013 3.
- A study published in 2006 4 found that high ADMA plasma concentrations independently predict major adverse cardiovascular events in patients with advanced peripheral artery disease.
- Overall, the ADMA test can be a useful tool in assessing cardiovascular risk and guiding treatment decisions, as supported by the study published in 2009 5.